BeOne Medicines Ltd. (Stock Code: 06160) has published a notice of internet availability of proxy materials for its 2026 Annual General Meeting (AGM), satisfying Hong Kong Listing Rule 13.10B disclosure requirements.

The proxy statement, proxy card and the 2025 Form 10-K are accessible at https://ir.beonemedicines.com/filings-financials/shareholder-meeting-materials. Shareholders may request hard copies free of charge by 1 June 2026 via +1 (877) 828-5568 or ir@beonemed.com.

The AGM will be held at 3:30 p.m. Swiss time on 11 June 2026 at the offices of Homburger AG, Prime Tower, Zürich. Only holders of record on 22 May 2026 are entitled to attend and vote.

Key agenda items (20 in total) include:

• Approval of the audited Swiss statutory standalone and consolidated financial statements for FY 2025 and appropriation of the accumulated loss. • Discharge of the Board of Directors and Executive Management Team from liability under Swiss law. • Re-election of seven existing directors and election of three new directors (Dr. Felix J. Baker, Ms. Elizabeth F. Mooney and Dr. Charles L. Sawyers) for terms ending at the 2027 AGM. • Re-election of Mr. John V. Oyler as Board Chairman and designation of Dr. Margaret Dugan and Ms. Elizabeth F. Mooney to the Compensation Committee. • Appointment of Schweiger Advokatur/Notariat as Independent Voting Representative. • Ratification of Ernst & Young’s global network firms as independent auditors for 2026 and authorization for the Board to set audit fees. • Advisory votes on executive compensation and on the Swiss Statutory Compensation and Non-Financial Matters Reports for FY 2025. • Approval of maximum aggregate compensation limits for the Board and Executive Management Team (FY 2027). • Amendments and restatements of the 2016 Share Option and Incentive Plan, including a consultant sub-limit, and the 2018 Employee Share Purchase Plan. • Granting of a general mandate allowing the Board to issue, allot or deal with unissued shares and/or ADSs up to 20 % of issued share capital (excluding treasury shares) until the next AGM, and a separate mandate to repurchase up to 10 % of issued shares (excluding RMB shares and treasury shares) within the same period. • Authorization for the Company and its underwriters to allocate shares to Amgen Inc. to maintain Amgen’s proportional holding for up to five years, subject to non-Amgen shareholder approval and annual renewal. • Authority for the chairman to adjourn the meeting to solicit additional proxies if required.

The Board of Directors unanimously recommends shareholders vote “FOR” each director nominee and “FOR” all other resolutions.